Category: Treatments & Therapies

The BOA’s Four New Commissioning Guides

The British Orthopaedic Association (BOA) is pleased to announce the recent publication of four revised commissioning guides with the Royal College of Surgeons of England. These NICE-accredited guides set out best practice care pathways to assist CCGs in designing optimal care for their populations. We are extremely grateful to all those involved in the rigorous development and accreditation processes. The guides, which can be found here, are:

  • Pain Arising from the Hip in Adults
  • Painful Deformed Great Toe in Adults
  • Painful Osteoarthritis of the Knee
  • Treatment of Carpal Tunnel Syndrome

Following the recent BOA and ARMA position statements on the rationing of elective orthopaedic services, we are urging stakeholders to consider these guides and to promote their adoption wherever appropriate with local CCGs.…

Read more of this article

A Guide to Rheumatology: Parliamentary briefing

In late September, BSR are releasing ‘A Guide to Rheumatology: Parliamentary briefing,’ which seeks to address the challenges and opportunities faced by the rheumatology multidisciplinary team and identify ways to improve the treatment and care received by individuals with rheumatic and musculoskeletal diseases. It highlights the significant difficulties experienced by rheumatology services and the patients they serve: 

  • Waiting times: 38% of patients in England with suspected rheumatoid arthritis were assessed within three weeks of referral.
  • Diagnostic delay: Only 18% of patients in England were referred to rheumatology within the NICE recommended three days of presentation to their GP.
…

Read more of this article

ARMA Policy Position Paper on Joint Replacement Surgery

In early August, ARMA has published a Policy Position Paper titled:

‘Rationing’ Access to Joint Replacement Surgery and Impact on People with Arthritis and Musculoskeletal Conditions [document opens in pdf]

It deals with the damaging nature of thresholds and scoring tools, the problems of waiting times and restricted access to surgery, and how patients with musculoskeletal conditions are affected.

The Alliance is drawing attention to worrying trends in treatment access and the paper makes clear the key outcomes we are seeking from CCGs and the NHS.

A new addition to the LUPUS UK range of publications

In July LUPUS UK released the newest edition in their range of publications, ‘LUPUS: Bone Health & Osteoporosis’.

The factsheet was kindly written by Dr David Armstrong (Consultant Rheumatologist, Altnagelvin Hospital, Londonderry).

This factsheet can be downloaded from the LUPUS UK website at www.lupusuk.org.uk/publications/ and physical copies are available from the National Office in Romford.

GP eLearning course for AS diagnosis

The current delay to diagnosis of ankylosing spondylitis (AS) stands at 8.5 years. NASS are committed to reducing this delay to diagnose. There are many factors impacting on this delay but an important issue is the recognition of AS in primary care and prompt referral on to rheumatology.

NASS have worked in partnership with the British Society for SpondyloArthritis (BRITSpA) to sponsor an eLearning course on ankylosing spondyloarthritis (axial spondyloarthritis) (AS) on the Royal College of General Practitioners (RCGP) website. The course aims to educate GPs about AS.…

Read more of this article

NICE Technology appraisal on bisphosphonates for osteoporosis

On 10th July 2017, NICE issued a new Technology Appraisal (TA) for bisphosphonates which links the recommendations for drug treatments to advice on fracture risk assessment outlined in their earlier guidance. The TA is not intended to provide treatment thresholds but offers recommendations on cost-effective use of bisphosphonates when using fracture risk assessment as described in their guideline www.nice.org.uk/guidance/cg146.

For the first time, these recommendations will apply to men as well as women.

The TA says that provided an individual meets the criteria for fracture risk assessment there should be no financial barrier to them receiving bisphosphonates if they have a fracture risk of at least 1% using FRAX or QFracture.…

Read more of this article

Belimumab (Benlysta) approved for restricted use in NHS Scotland

On Monday 8th May 2017 the Scottish Medicines Consortium (SMC) published new advice accepting the restricted use of belimumab (Benlysta) by NHS Scotland for lupus patients. This advice was published following a re-submission with evidence supplied by GlaxoSmithKline (the producers of Benlysta) and LUPUS UK on behalf of patients.

 

Belimumab is the first drug approved to treat lupus in more than 50 years and is the first drug developed specifically for lupus since the disease was discovered. It is approved for adults with active, systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines.…

Read more of this article

HUG/ARMA Stoke Meeting

Geoffrey Lawton, Stoke ARMA group chair, invites you to:

The HUG/ARMA group meeting on 19th May 2017

at 1pm, in the Lecture room of

Haywood Hospital, Burslem, Stoke on Trent ST6 7AG

 

Refreshments will be provided from 12:45pm and drinks during the meeting.

A wide range of topics are on the agenda including presentations on all aspects of Arthritis-related treatments.

Whether you are an elite athlete, weekend warrior or an everyday active person the musculoskeletal care pathway for rehabilitation is the same

Guest Blog by Dr Jo Larkin, Sport and Exercise Medicine Consultant FFSEM

The knowledge and principles used to treat elite professional athletes in Sport and Exercise Medicine can be used to treat injuries occurring in the rest of the population.

The musculoskeletal (MSK) rehabilitation plan must consider the fact that the objective of the patient is to return to the same activity and environment in which the injury occurred. Functional capacity after rehabilitation should at the minimum be to at the same level, if not better, than before injury.…

Read more of this article

Updated LUPUS UK Publications

In the past month LUPUS UK has published updated versions of three of our information leaflets/booklets. These publications were updated to ensure that they meet the requirements of the Information Standard and reflected the most up-to-date evidence.

Physical copies are available to order free of charge from LUPUS UK National Office, or you can read/download them on our website by following the hyperlinks:

 

Contribution to the Scottish Medicines Consortium’s (SMC) consultation of the use of Benlysta (belimumab) in SLE

Benlysta (belimumab) is due to be discussed by the SMC and a decision made for its use by certain SLE patients in Scotland.…

Read more of this article